Key result
Carriers of the NLRP3 rs4612666 C variant exhibited increased expression of pro-inflammatory cytokines in visceral adipose tissue and higher oxidative stress compared to non-carriers.
Why the study?
NLRP3 inflammasome activation plays a central role in obesity-induced inflammation, but the influence of NLRP3 and CARD8 genetic variants on visceral adipose tissue inflammation and systemic oxidative stress around sleeve-gastrectomy was unknown.
Does the NLRP3 rs4612666 C variant influence visceral adipose tissue inflammation and oxidative stress in severe obese patients undergoing sleeve-gastrectomy?
Observational (n=23)
Does the NLRP3 rs4612666 C variant influence visceral adipose tissue inflammation and oxidative stress in severe obese patients undergoing sleeve-gastrectomy?
The NLRP3 rs4612666 C variant is associated with a worse pro-inflammatory profile and higher oxidative stress in severe obese patients, though sleeve gastrectomy improves these parameters regardless of genotype.
May inform cardiometabolic risk models; leaves open whether NLRP3 genotyping predicts outcomes or guides therapy.
BACKGROUND: The activation of NLRP3 inflammasome machinery has a central role in obesity-induced inflammation. Genetic studies well support the involvement of functional variants of NLRP3 and its negative regulator, CARD8, in the pathogenesis of complex diseases with an inflammatory background. We have investigated the influence of NLRP3 (rs4612666; rs10754558) and CARD8 (rs204321) genetic variants in both the inflammatory status of visceral adipose tissue (VAT) from patients with severe obesity and in the systemic oxidative stress before and after sleeve-gastrectomy (SLG). METHODS: Twenty-three consecutive severe obese patients candidate to SLG were enrolled in the study. Visceral adipose tissue (VAT) biopsies, obtained during SLG, were used to evaluate the expression of NLRP3, IL-1β, IL-6, and MCP-1 by real-time RT-PCR. DNA was extracted from peripheral blood lymphocytes and genotyped by RFLP analysis. Before and 3 months after SLG, all patients underwent the assessment of oxidative stress, biochemical parameters, and body composition as measured by bioelectrical impedance analysis (BIA). RESULTS: Increased expression of NLRP3, IL-6, IL-1β, and MCP-1 mRNA was observed in VAT of rs4612666 C variant carriers, in which higher oxidative stress was also detected as compared to non-carrier individuals. In all patients, oxidative stress, biochemical and BIA parameters improved after SLG, regardless of genotype. No significant correlations were found with the other genetic variants. CONCLUSIONS: Our results suggest that the NLRP3 rs4612666 C variant may promote a worse pro-inflammatory milieu and higher oxidative stress, thus leading patients to a more severe obesity phenotype. A larger study is needed to confirm this assumption and to investigate the impact of the NLRP3 rs4612666 C variant on severe obesity.
No takes yet. Share an insight, caveat, or question.
Perri et al. (2021) conducted an observational in Severe obesity (n=23). NLRP3 rs4612666 C variant vs. Non-carrier individuals was evaluated on Expression of NLRP3, IL-1β, IL-6, and MCP-1 in visceral adipose tissue and systemic oxidative stress. Carriers of the NLRP3 rs4612666 C variant exhibited increased expression of pro-inflammatory cytokines in visceral adipose tissue and higher oxidative stress compared to non-carriers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: